Medarex and Compugen are partnering to develop Mab-based therapeutics for oncology and autoimmune diseases.
Compugen expects to utilize its antibody-target discovery engine to identify drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System®.
The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.
Under the terms of the agreement, Medarex and Compugen plan to share discovery, development, and commercialization responsibilities as well as revenues generated from the sale of any therapeutic products resulting from this collaboration.